Previous studies have also extensively investigated various biomarkers to predict immunotherapy response and prognosis in GC, such as PD-L1 expression (35), tumor mutational burden (36), MSI status (37), Epstein-Barr virus infection (38), circulating tumor DNA (ctDNA) (35), gut microbiota (38), Peripheral Blood Biomarkers (38), Gene Expression Profile (38) and radiomics-derived signatures (39). This evidence concerns the gene CD274 and neoplasm.